The following are questions the multi-millions sha
Post# of 22453
A great collection of questions put together by Kurt.
Quote:
QMC's bylaws require annual meetings with the election of directors. https://www.sec.gov/Archives/edgar/data/14035.../ex3-2.htm
It's been years since either has happened. Maybe there is no option other than to increase the A/S. The same is not true for the slate of directors proposed. If the proxy doesn't include the election of directors, shareholders have the right to demand one, and there are a lot of questions that need answers before directors are elected.
Some questions that I think should be answered before voting on any proposed directors:
- Who are the current directors of the company (including bios and all equity ownership details)?
- If new directors are proposed, what is their relevant experience and how will they be compensated?
- Who are the current elected officers of the company (including all equity ownership and compensation details)?
- Are there any agreements with Amtron or other partners in India that have not been disclosed, and if so, can/will they be disclosed now?
- If there are other agreements in India, is the one with Amtronics CC that was disclosed still in effect? Are any parts of it overridden by other agreements, if so which parts?
- Have the reactors that were sent to India been set-up, and if so, have they produced any commercially viable product, and if so, have they produced any sales?
- Can the agreements with Les Paull and QMVT be disclosed? If so, will the company disclose them now?
- What is the status of the agreements with Les Paul and QMVT? Are there any current defaults with QMC that would ordinarily be disclosed in a 10-K or Q? If so, what?
- Who are the directors of QMVT? Are there any shareholder agreements or other agreements that involve the directors or officers of QMC?
- Where is the company exactly in the process of preparing and auditing it's financial statements? What has been accomplished and what remains?
- The auditors have been blamed, at least in part, for the late financials. What exactly did they do/not to and how exactly did those fault(s) contribute?
- What is the expected timeline to completion of the outstanding financials? If no timeline can be given, what is the source of the uncertainty?
- Will the company give updates that includes the delinquent financials as they are completed?
- If an S-1 is filed, will it register all the shares or only certain shares? If only certain shares, whose and, what is the plan for shareholders not covered by the S-1?
- What is a realistic date for re-registration of the company's shares?
- What changes have been made to assure that the company will stay current in it's filings after re-registration?
- What is the status with the previously disclosed agreements with Pasaca? How much, if any, money was funded? How many shares are owed to Pasaca?
- Does the company have a demonstrated, commercially viable QDSC design and manufacturing process?
- What is a realistic scenario for POCT commercialization? Do any/all of the products currently being developed require FDA approval?
- How many patent applications have been filed that have yet to be published on the USPTO website?
- How many shares is the company currently over the A/S, including options, warrants, and convertibles outstanding?
- Are there any disclosures that would be required in a 10-K that are not covered by these questions? If so, what?
I'm sure there are others.